MedTrace Logo

Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy

NCT05064111 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-03

No results posted yet for this study

Summary

The purpose of this study is to utilize this technology in the early detection and staging of pathologic states within prostate cancer patients using the information obtained on mpMRI and serum biomarkers from the patient's blood (if collected). Ultimately, investigators hope to improve the diagnostic accuracy and treatment selection process for these patients. Applying the fusion software which adds mpMRI to ultrasound images in real time, to an otherwise clinically standard but non-targeted ultrasound-guided prostate biopsy procedure will help with accurate and early diagnosis of prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

TRUS biopsy

The biopsy procedure will be completed using an FDA-approved ultrasound machine with the addition of an investigational (non-FDA approved) image fusion software.

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Principal Investigators

  • Hina Arif-Tiwari, MD · University of Arizona

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-01
Primary Completion
2027-11-01
Completion
2028-11-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05064111 on ClinicalTrials.gov